The group's principal activity is to develop monoclonal antibody-based therapeutic products for the treatment of cancer and immunologic diseases. Its diverse portfolio of product candidates includes sgn-30 and sgn-15 in phase ii clinical development and sgn-40 in phase i clinical trials. In addition, it has three product candidates currently in preclinical development, sgn-35, sgn-75 and sgn-17/19. The product candidates are based on three technologies: genetically engineered monoclonal antibodies, monoclonal antibody-drug conjugates (adcs) and antibody-directed enzyme prodrug therapy (adept).
